Epizyme ensures the new therapy for cancer treatment

enVision - the future of disease diagnostics

Transforming the lives of patients with cancer and immune disorders

The technology treats chronic diseases by addressing the underlying cause of the disease

Potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases were developed by Intellia Therapeutics. This company is spinoff of Harvard University. Intellia Therapeutics is focused on positively disrupting health care treatment of patients with genomic diseases. Conventional medicines treat the symptoms instead of the genetic cause of severe and life-threatening diseases, meaning that patients must take these therapies throughout their lives. Intellia is revolutionizing medicine by harnessing the power of genome editing to develop potential cures. They bring new hope for people living with conditions including cancer (lat. Carcinoma), genetic disorders, viral infections, inflammatory disorders and many more.

by
15 hours ago

New medicines for bone marrow transplantation

The novel medicines to transform all aspects of bone marrow transplant were developed by Magenta Therapeutics. This company is spinoff of Harvard University. Significant needs remain for patients living with autoimmune diseases, blood cancers (lat. Sanguis Carcinoma), and rare genetic diseases. A bone marrow transplant is a potential cure for many, but its high risks, toxic side effects and complexity prevent many patients from being able to benefit. Magenta Therapeutics is working comprehensively across the transplant journey to change this reality. The company aims to address significant needs across all aspects of transplant medicine. By pioneering an innovative portfolio of novel therapeutics designed to make the entire bone marrow transplant process more effective, safer and easier, they aim to unleash the full potential of bone marrow transplant for patients with multiple sclerosis, scleroderma, acute myeloid leukemia, myelodysplastic syndromes, inherited metabolic diseases, and sickle cell disease.

by
15 hours ago

New test can predict spread of breast cancer

The test, which could help doctors precisely identify breast cancer (lat. Pectus Carcinoma) patients should receive aggressive therapy, thereby sparing many women at low risk for metastatic disease from undergoing unnecessary and potentially dangerous treatment, was developed by scientists at MIT, the Albert Einstein College of Medicine and Weill Cornell Medical School. The researchers, including MIT biology professor Frank Gertler, developed the test based on an earlier finding that the co-mingling of three cell types can predict whether localized breast cancer will metastasize, or spread throughout the body.

by
15 hours ago

Precision BioSciences is dedicated to fighting cancer

First-in-class therapies that modulate historically recalcitrant cancer targets

The novel immuno-oncology platform

The first major advances in hemophilia treatment

The new treatment for hemophilia (lat. Haemophilia, also spelt as hemophilia) was developed by Bioverativ, a Sanofi company. This company is dedicated to transforming the lives of people with hemophilia, cold agglutinin disease and other rare blood disorders. Their hemophilia therapies were the first major advancements in the treatment of hemophilia A and B in nearly two decades, and today, they are the leading extended half-life therapies. The company goal is to impact more lives of people with hemophilia. Already, more than 3,000 people have chosen Bioverativ’s extended half-life therapies and more than 12,000 people, including children, have been provided access to novel factor VIII and IX products.

by
15 hours ago

The curative gene therapy for treating hemophilia

uniQure, Amsterdam UMC (AUMC) spinoff, developed the new potential therapy for the treatment of hemophilia (lat. Haemophilia, also spelt as hemophilia). The company is delivering on the promise of gene therapy, single treatments with potentially curative results. The team of uniQure has developed a modular technology platform to rapidly bring new disease-modifying therapies to patients with severe genetic diseases. They are advancing a focused pipeline of innovative gene therapies and have established clinical proof-of-concept in lead indication, hemophilia B, and preclinical proof-of-concept in Huntington’s disease. Their pipeline of adeno-associated virus (AAV)-based gene therapies has been developed using an innovative technology platform, supported by industry-leading proprietary commercial-grade manufacturing capabilities. Through recent collaborations and strategic partnership, the company has taken the next steps toward developing gene therapies targeting chronic and degenerative diseases that affect larger populations.

by
15 hours ago

The new drug for hemophilia A

The technique that could cure hemophilia (lat. Haemophilia, also spelt as hemophilia) was developed by Octapharma. The company develops and manufactures high-purity coagulation factor concentrates for patients with bleeding disorders. These plasma products are produced to the highest standards, using the latest technology, in state of the art manufacturing facilities to ensure the most advanced solutions are available to patients globally. In people with Bleeding disorders, clotting factors like Factor VIII, Factor IX or von Willebrand factor (VWF) are missing or don't work as they should. This causes these people to bleed for a longer time than those whose blood factor levels are normal. Early on-demand or prophylactic therapy that replaces the missing coagulation factor is able to effectively control or prevent acute bleeding in this group of patients.

by
15 hours ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

#1 VENTURE CLIENT PLATFORM